生体部分肝移植後<i>de novo</i>悪性腫瘍の検討

• 原村 智子

  長崎大学大学院移植・消化器外科

• 曽山 明彦

  長崎大学大学院移植・消化器外科

• 高槻 光寿

  長崎大学大学院移植・消化器外科

• 虎島 泰洋

  長崎大学大学院移植・消化器外科

• 足立 智彦

  長崎大学大学院移植・消化器外科

• 北里 周

  長崎大学大学院移植・消化器外科

• 木下 綾華

  長崎大学大学院移植・消化器外科

• 夏田 孔史

  長崎大学大学院移植・消化器外科

• 松島 肇

  長崎大学大学院移植・消化器外科

• 井上 悠介

  長崎大学大学院移植・消化器外科

• 黒木 保

  長崎大学大学院移植・消化器外科

• 江口 晋

  長崎大学大学院移植・消化器外科

書誌事項

タイトル別名

• <i>De novo</i> malignancy following living donor liver transplantation

抄録

【Objective】Patients who have undergone organ transplantations are considered to be at risk for developing malignancies resulting from prolonged immunosuppression. However, the incidence and the most common sites of such malignancies following living donor liver transplantation (LDLT) remain unclear. We investigated patients who developed de novo malignancies after undergoing LDLTs at our institute.<br/>【Design】Case series.<br/>【Methods and patients】From August 1997 to March 2012, a total of 156 patients underwent LDLT. Among these patients, those with de novo malignancy were analyzed in detail.<br/>【Results】Nine of our 156 patients developed de novo malignancies (5.8%). The median age at LDLTs was 57 years (range: 0-65 years). The de novo malignancies included squamous cell carcinoma (SCC), gastric cancer, pancreatic cancer, lung squamous cell carcinoma, colon cancer, renal cell carcinoma, ameloblastoma, oral cancer and Langerhans histiocytosis. Seven patients were successfully treated with surgical resection. One patient with pancreatic cancer already had liver metastasis at the time of diagnosis and was treated with chemotherapy. However, he died 22 months after the diagnosis of malignancy. One patient with Langerhans histiocytosis was treated with chemotherapy that induced a remission; however, she later died as a result of liver failure.<br/>【Conclusions】SCC, which has frequently been reported as a de novo malignancy in patients who have undergone liver transplantations in Western countries, also developed in this series, as mentioned. However, SCC has so far been only rarely reported in Japan as a malignancy after LDLT, so it is difficult to precisely clarify the ratio of the number of SCCs in all malignancies after LDLT in comparison with the general population. Considering the differences in the patients' race and ethnicity, and also the frequency of the different surgical procedures performed between Europe and Japan, we therefore find that a national registry should be established to clarify the details of de novo malignancies in Japan.

収録刊行物

• 移植

  移植 48 (6), 395-399, 2013

  一般社団法人 日本移植学会

キーワード

• liver transplantation
• <i>de novo</i> malignancy
• surveillance

詳細情報

• CRID: 1390282680485890816
• NII論文ID: 130005002792
• DOI: 10.11386/jst.48.395
• ISSN: 21880034
• ISSN: 05787947
• Web Site: https://search.jamas.or.jp/link/ui/2014141015
• 本文言語コード: ja
• データソース種別:
  • JaLC
  • CiNii Articles
• 抄録ライセンスフラグ: 使用不可